The preclinical bioanalytical testing services market was valued at USD million in 2025, expanding at a CAGR of 10.80% by 2035. An expanding volume of drug candidates demands rigorous pharmacokinetic (PK), toxicokinetic (TK), and biomarker evaluations before human clinical trials. This report was curated by our healthcare research analyst, Deepa Pandey. Her research is useful for healthcare providers, medical product manufacturers, biotechnology firms, and investors for competitive benchmarking and strategic decision-making.